15. EFFIECIENCY OF INTRAOSSEOUS VANCOMYCIN PROPHYLAXIS IN TOTAL KNEE ARTHROPLASTY
Main Article Content
Abstract
Introduction: Intraosseous (IO) vancomycin prophylaxis in total knee arthroplasty has been shown to increase local vancomycin concentration, lower systemic adverse effect, help prevent periprosthetic joint (PJI) infection, especially MRSA (methicillin-resistant Staphylococcus aureus).
Materials and Methods: A retrospective review of 1279 patients underwent total knee arthroplasty at Tam Anh HCM hospital (01/2022-05/2024) with at least 90 days follow-up. There were 795 patients in non-IO group and 484 patients in IO group. The IO group received a 500mg vancomycin mixed with 120ml NaCl 0.9%, injected in proximal tibia after tourniquet, before skin incision. Both groups received prophylaxis cephalosporin and same post-operative treatments.
Results: There are 11 PJI (1.38 %) in non-IO group and 1 PJI (0.2%, p=0.037) in IO group. There were no systemic adverse events in IO group, local vancomycin concentrations were high at beginning and before closure of the surgery.
Conclusions: Intraosseous vancomycin prophylaxis provided a safe and effective, simple way to prevent periprosthetic joint infection in total knee arthroplasty.
Article Details
Keywords
Intraosseous (IO), periprosthetic joint infection, total knee arthroplasty (TKA), antibiotic prophylaxis, vancomycin
References
[2] Sandiford, N., M. Franceschini, and D. Kendoff, The burden of prosthetic joint infection (PJI). Annals of Joint, 2021. 6.
[3] van Veghel, M.H.W., et al., Early Periprosthetic Joint Infections in Total Hip and Knee Arthroplasty: Microorganisms, Mortality, and Implant Survival Using a Combined Dataset From the Dutch Arthroplasty Register and the Dutch National Nosocomial Surveillance Network. J Arthroplasty, 2024.
[4] Crawford, T., K.A. Rodvold, and J.S. Solomkin, Vancomycin for Surgical Prophylaxis? Clinical Infectious Diseases, 2012. 54(10): p. 1474-1479.
[5] Young, S.W., et al., The Mark Coventry Award: Higher tissue concentrations of vancomycin with low-dose intraosseous regional versus systemic prophylaxis in TKA: a randomized trial. Clin Orthop Relat Res, 2014. 472(1): p. 57-65.
[6] Premkumar, A., et al., Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States. J Arthroplasty, 2021. 36(5): p. 1484-1489.e3.
[7] Clarke, M.T., et al., Contamination of primary total hip replacements in standard and ultra-clean operating theaters detected by the polymerase
chain reaction. Acta Orthop Scand, 2004. 75(5): p. 544-8.
[8] Alomar, A.Z., et al., INTRAOPERATIVE EVALUATION AND LEVEL OF CONTAMINATION DURING TOTAL KNEE ARTHROPLASTY. Acta Ortop Bras, 2022. 30(spe1): p. e243232.
[9] Hill, C., et al., Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial. Lancet, 1981. 1(8224): p. 795-6.
[10] Spangehl, M.J., et al., Higher Tissue Concentrations of Vancomycin Achieved With Low-Dose Intraosseous Injection Versus Intravenous Despite Limited Tourniquet Duration in Primary Total Knee Arthroplasty: A Randomized Trial. J Arthroplasty, 2022. 37(5): p. 857-863.
[11] Haseeb, A., et al., A Systematic Review on Clinical Safety and Efficacy of Vancomycin Loading Dose in Critically Ill Patients. Antibiotics (Basel), 2022. 11(3).
[12] Polk, R.E., et al., Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis, 1988. 157(3): p. 502-7.
[13] Parkinson, B., et al., Intraosseous Regional Prophylactic Antibiotics Decrease the Risk of Prosthetic Joint Infection in Primary TKA: A Multicenter Study. Clin Orthop Relat Res, 2021. 479(11): p. 2504-2512.
[14] Burke, J.F., The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery, 1961. 50: p. 161-8.